期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

颈及胸上段食管癌同步加量调强放疗的剂量学研究 被引量：8

Dosimetric study of simultaneous integrated boost intensity-modulated radiotherapy for cervical and upper thoracic part esophageal carcinoma
下载PDF
导出
摘要 对7例颈及胸上段食管癌患者分别设计3、5、7野3种同步加量调强放疗的设野计划,比较3种计划间靶区和危及器官的剂量学差异。结果显示3野计划的靶区覆盖率、适形指数和均匀性指数明显劣于5野和7野。7野计划中双肺V5明显大于3野和5野。表明3野计划即可使颈及胸上段食管癌的治疗靶区得到足够的照射剂量,但均匀性及适形度差,5野计划可使靶区获得较为理想的剂量分布,可作为临床首选。 Seven cervical part and upper thoracic part esophageal carcinoma patients were respectively designed for 3 ,5 ,7 fields in simultaneous integrated boost intensity-modulated radiotherapy plans to compare the differences in target and organ at risk dose. Results revealed that the target area dose coverage,conformity index and homogeneity index in 3 fields plans were inferior to 5 fields and 7 fields plans. Moreover, the both lung V5 in 7 fields plan was greater than 5 fields and 3 fields plans. The target area could receive sufficient dose in 3 fields plan, but the uni-formity and conformity were unsatisfied. 5 fields plan made the target area receive ideal dose distribution, which showed 5 fields plan was the first choice in clinic.
作者 蒋俊 权循凤 洪浩 李锐
机构地区 安徽医科大学第一附属医院肿瘤放疗科
出处 《安徽医科大学学报》 CAS 北大核心 2014年第3期392-394,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽省教育厅自然科学重点项目(编号:KJ2010A170)
关键词 食管癌 同步加量 调强放疗 剂量学 esophageal neoplasm simultaneous integrated boost intensity-modulated radiotherapy dosimetry
分类号 R730.55 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Mundt A J, Mell L K, Roeske J C. Preliminary analysis of chronic gastrointestinal toxicity is gynecology patients treated with intensity-modulated whole pelvic radiation therapy [J]. Int J Radiat Oncol Bioi Phys,2003,56(5) :1354 -60.
  • 2Fultz P J, Feins R H, Strang J G, et al. Detection and diagnosis of nonpalpable supraclavicular lymph nodes in lung cancer at CT and US[J]. Radiology,2002,222(1) :245 -51.
  • 3Welsh J, Palmer M B, Ajani J A, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique [J].. Int J Radiat Oncol Bioi Phys,2012 ,82(1) :468 -74.
  • 4Geier M, Astner S T, Duma M N, et al. Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy[J]. Strahlenther Onkol,2012,188(5) :410 -6.
  • 5Cilia S, Caravatta L, Picardi V, et al. Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer] J]. Clin Oncol (R Coli Radiol ) ,2012,24 ( 4 ) : 261 - 8.
  • 6McDonald M W , Godette K D, Whitaker D J, et al. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost [J]. Int J Radiat Oncol Bioi Phys , 2010 ,77 (2) :523 -30.
  • 7Chen W, He Y, Zheng R, et al. Esophageal cancer incidence and mortality in China,2009[J].. J Thorac Dis,2013,5(1) :19 -26.
  • 8李建成,张和平,刘迪,陈诚.成人正常食管壁厚度CT测量结果分析[J].中国肿瘤,2010,19(11):758-759. 被引量：2
  • 9裘国勤,杜向慧,郑远达,罗浩杰,许亚萍,陈建祥,孙晓江,季永领.28例颈、胸上中段食管鳞癌同期加量调强放疗的近期疗效及毒副反应[J].肿瘤学杂志,2010,16(1):30-34. 被引量：9

二级参考文献23

  • 1Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus [J]. N Engl J Med, 1992, 326(24):1593-1598.
  • 2Kato H, Watanabe H, Tachimori Y, et al. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma[J]. Ann Thorac Surg, 1991, 51 (6) : 931-935.
  • 3Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus[J]. J Clin Oncol, 2003, 21 (14):2697-2702.
  • 4Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase m trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy[J]. J Clin Oncol, 2002, 20(5):1167-1174.
  • 5Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma[J]. Am J Surg, 2005, 189(1):98-109.
  • 6Tabira Y, Yasunaga M, Tanaka M, et al. Recurrent nerve nodal involvement is associated with cervical nodal metastasis in thoracic esophageal carcinoma[J]. J Am Coil Surg, 2000, 191(3):232-237.
  • 7Kawahara K, Maekawa T, Okabayashi K,et al. The number of lymph node metastases influences survival in esophageal cancer[J]. J Surg Oncol, 1998, 67(3):160-163.
  • 8Toita T, Ogawa K, Adachi G, et al. Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high-dose external beam boost irradiation [J]. Jpn J Clin Oncol, 2001, 31(8):375-381.
  • 9Onozawa M, Nihei K, Ishikura S, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus [J]. Radiother Oncol, 2009, 92(2):266-269.
  • 10Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma [J]. Int J Radiat Oncol Biol Phys, 2009, 75(1):122-128.

共引文献9

同被引文献71

  • 1Nutting CM,Bedford JL,Cosgrove VP,et al.A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy[J].Radiother Oncol,2001,61(2):157-163.
  • 2Carmeliet P,Jain PK.Angiogenesis in cancer and other disease[J].Nature,2000,407(6801):249-257.
  • 3Takagi M,Sakata K,Someya M,et al.Gimeracil sensitizes cells to radiation via inhibition of homologous recombination[J].Radiother Oncol,2010,96(2):259-266.
  • 4Ogawa K,Chiba I,Morioka T,et al.Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy[J].Anticancer Res,2011,31(6):2351-2359.
  • 5Hiroshi Harada,Masahiro Hiraoka.Hypoxia-inducible factor 1 in tumor radioresistance[J].Current signal transduction therapy,2010,5(3):188-196.
  • 6Zeng L,Ou G,Itasaka S,et al.TS-1 enhances the effect of radiotherapy bysuppressing radiation-induced hypoxia-induciblefactor-1activation and inducing endothelial cellapoptosis[J].Cancer Sci,2008,99(11):2327-2335.
  • 7Chen W, He Y, Zheng R, et al. Esophageal cancer incidence and mortality in China, 2009[ J]. J Thorac Dis,2013, 5( 1 ) : 19 -26.
  • 8Mazzola R, Ferrera G, Alongi F, et al. Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience[ J]. Radiol Med,2015, 120(8) : 753-758.
  • 9Nour AA, Alaradi A, Mohamed A, et al. Intensity modulated ra- diotherapy of upper abdominal malignancies : dosimetric compari- son with 3D conformal radiotherapy and acute toxicity[ J]. Radiat Oncol,2013, 8(1) : 207.
  • 10Yamazaki H, Nakamura S, Nishimura T, et al. Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis [ J ]. J Radiat Res, 2014, 55(6): 1033-1047.

引证文献8

二级引证文献44

安徽医科大学学报
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部